Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)

Yi Min Liu, Chun Nan Kuo, Jing Ping Liou

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase, has been discovered in several cancers, including anaplastic large-cell lymphoma, non-small cell lung cancer, and inflammatory myofibroblastic tumors. The deregulation of ALK activities, such as translocation and point mutation, results in human carcinogenesis. The use of ALK inhibitors in clinical cancer treatment has been shown to be efficacious, and the issue of resistance to ALK inhibitors has been reported. Consequently, the development of a new generation of ALK inhibitors is necessary. Areas covered: This paper provides a comprehensive review of the patent literature from 2014 to 2018 including small molecule ALK inhibitors and their use as anticancer agents. The approved and developing ALK inhibitors are described. Expert commentary: The available three generations of ALK inhibitors have shown a good anticancer effect in ALK-positive non-small cell lung cancer. An urgent issue in this field is ALK resistance development. The development of new ALK inhibitors through structure modification of currently available ALK inhibitors is proceeding, such as the synthesis of macrocyclic compounds. This article arranges the ALK inhibitors that have published in the patent in recent years. It may help in the investigation of a new generation of ALK inhibitors, which can overcome the resistance issue and development of novel drug candidates in the future.

Original languageEnglish
JournalExpert Opinion on Therapeutic Patents
DOIs
Publication statusAccepted/In press - Jan 1 2020

Keywords

  • anaplastic large-cell non-Hodgkin’s lymphoma
  • Anaplastic lymphoma kinase
  • cancer
  • non-small cell lung cancer
  • small molecule inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)'. Together they form a unique fingerprint.

Cite this